12 completed, 5 recruiting, 2 active not recruiting, 1 not yet recruiting. 14 Phase 1, 4 Phase 2, 2 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 9, Active not recruiting 2, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 4 | Completed 2, Recruiting 2 |
| Early Phase 1 | 2 | Completed 2 |
| Not applicable | 1 | Recruiting 1 |
Follow N,N-Dimethyltryptamine: new trials by email Literature Review of N,N-Dimethyltryptamine trials Research Report on N,N-Dimethyltryptamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) N,N-Dimethyltryptamine (15 mg), N,N-Dimethyltryptamine (17.5 mg) - Healthy Participants Study | Phase 1 | Not yet recruiting | Jon Dean | 20 | 2026-09-01 | 2026-07-09 |
| Inhaled DMT for Major Depressive Disorder N,N-Dimethyltryptamine (15 mg + 60 mg), N,N-Dimethyltryptamine (1 mg + 4 mg) - MDD, Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Universidade Federal do Rio Grande do Norte | 140 | 2026-08-01 | 2026-07-13 |
| The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease Psilocybin (drug) - Depression, Parkinson's Disease (PD) | Phase 2 | Recruiting | Yale University | 40 | 2026-07-10 | 2026-09-28 |
| Antidepressant Response of DMT Masked With Propofol N,N-Dimethyltryptamine, Placebo, Propofol - Major Depressive Disorder, Psychedelic Experiences | Not applicable | Recruiting | University Hospital, Basel, Switzerland | 112 | 2025-08-05 | 2026-04-02 |
| The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion, 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion, 25 mg Diphenhydramine (5 min) + Normal Saline - Alcohol Use Disorder (AUD), Alcohol-Related Disorders | Phase 1 | Recruiting | Yale University | 63 | 2025-08-04 | 2026-09-10 |
| Investigation of Psychedelic Effects in Psychoactive Substances Placebo, Psilocybin, Ketamine - Psychedelic Effects in Healthy Volunteers | Phase 1 | Recruiting | Johns Hopkins University | 50 | 2025-02-05 | 2026-02-23 |
| Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study) N,N-Dimethyltryptamine (5mg), N,N-Dimethyltryptamine (10mg), N,N-Dimethyltryptamine (15mg) - Healthy | Phase 1 | Completed | University Hospital, Basel, Switzerland | 36 | 2024-06-12 | 2025-04-11 |
| Molecular Imaging Study of Harmine/DMT: a Basic Research Approach N,N-dimethyltryptamine (DMT) + harmine, Placebo - Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine | Phase 1 | Completed | Insel Gruppe AG, University Hospital Bern | 17 | 2024-01-22 | 2025-03-19 |
| Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression N,N-Dimethyltryptamine - Depressive Disorder, Depression, Unipolar | Phase 2 | Completed | Universidade Federal do Rio Grande do Norte | 14 | 2023-10-09 | 2024-05-08 |
| Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects Dimethyltryptamin (DMT) & Harmine - Healthy | Phase 1 | Completed | Reconnect Labs | 16 | 2023-05-05 | 2023-11-02 |
| Safety and Tolerability of DMT in Healthy Adults N,N-Dimethyltryptamine, Placebo - Safety Issues, Healthy Volunteers | Phase 1 | Completed | Universidade Federal do Rio Grande do Norte | 25 | 2023-04-26 | 2023-10-11 |
| Mindfulness and Psychedelics DMT + harmine, Placebo - Healthy Participants | Early Phase 1 | Completed | Milan Scheidegger | 40 | 2023-02-20 | 2023-09-21 |
| Single and Repeat Doses of DMT in Healthy Subjects N,N-Dimethyltryptamine, Placebo - Stroke | Phase 1 | Active not recruiting | Algernon Pharmaceuticals | 60 | 2023-01-13 | 2025-01-28 |
| SPL026 With or Without SSRIs in Participants With MDD SPL026 - Major Depressive Disorder | Phase 1 | Completed | Small Pharma Ltd | 18 | 2022-12-13 | 2024-06-14 |
| Acute Dose-dependent Effects of DMT in Healthy Subjects N,N-Dimethyltryptamine (54 mg), N,N-Dimethyltryptamine (108 mg), N,N-Dimethyltryptamine (162 mg) - Healthy | Phase 1 | Completed | University Hospital, Basel, Switzerland | 24 | 2022-11-15 | 2024-04-25 |
| Clinical Study of DMT in Healthy Adults N,N-Dimethyltryptamine - Healthy Volunteers | Phase 1 | Completed | Biomind Labs Inc. | 27 | 2022-06-01 | 2023-02-15 |
| Effects of Dimethyltryptamine in Healthy Subjects Dimethyltryptamine (DMT), Saline - Healthy | Phase 1 | Completed | University Hospital, Basel, Switzerland | 31 | 2021-06-18 | 2022-10-12 |
| Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans 0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT) - Major Depressive Disorder, Depression | Phase 1 | Active not recruiting | Yale University | 30 | 2021-03-17 | 2025-08-03 |
| SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients SPL026, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Completed | Small Pharma Ltd | 66 | 2021-02-04 | 2024-03-27 |
| Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects DMT, Harmine, Placebo (Harmine) - Emotions, Mood | Early Phase 1 | Completed | Psychiatric University Hospital, Zurich | 34 | 2020-12-01 | 2022-10-04 |
Depressive Disorder, Major (5) · Depression (3) · Alcohol Drinking (1) · Alcohol-Related Disorders (1) · Alcoholism (1) · Depressive Disorder (1) · Movement Disorders (1) · Parkinson Disease (1) · Stroke (1) · Suicidal Ideation (1) · Suicide (1)
University Hospital, Basel, Switzerland (4) · Universidade Federal do Rio Grande do Norte (3) · Yale University (3) · Small Pharma Ltd (2) · Algernon Pharmaceuticals (1) · Biomind Labs Inc. (1) · Insel Gruppe AG, University Hospital Bern (1) · Johns Hopkins University (1) · Jon Dean (1) · Milan Scheidegger (1) · Psychiatric University Hospital, Zurich (1) · Reconnect Labs (1)
Switzerland (8) · United States (5) · Brazil (4) · United Kingdom (2) · Netherlands (1)
Fabian Devlin, MD (2) · Anahita Bassir Nia, MD (1) · David Erritzoe, MD (1) · Draulio Araujo, Ph.D (1) · Draulio B. Araujo, Ph.D (1) · Erich Seifritz, Prof (1) · Fernanda Palhano-Fontes, Ph.D (1) · Frederick Barrett, Ph.D. (1) · Gabriel Jacobs, MD, PhD (1) · Jon Dean, PhD (1) · Malcolm Boyce, MD (1) · Marcelo Falchi, M.D. (1) · Matthias E Liechti, MD (1) · Matthias E Liechti, Prof. Dr. MD (1)
PMID 40484114, PMID 37086340, PMID 37221177, PMID 38089057, PMID 38274414, PMID 39340164, PMID 39774840, PMID 40258990, PMID 40337754, PMID 40356576, PMID 40375477, PMID 40532423, PMID 41699126, PMID 42220002, PMID 42649324, PMID 42768932
2018 (1), R21AA030649 (1)